Ozempic and other GLP-1 drugs show promise not only in managing obesity and diabetes but also in reducing Alzheimer’s risk. A study published in Alzheimer’s & Dementia reveals semaglutide lowers the risk of Alzheimer’s by 70% compared to insulin in Type 2 diabetes patients, spotlighting its potential in improving brain health.